Innovating the A of ADC: Breaking Down Mechanisms, Learnings & Clinical Prospect of Multispecific ADCs

  • Understanding the different avenues of innovation of masked and conditionally active ADCs to highlight ability to reduce on-target, off-tumor toxicity
  • Breaking down the principles and advantages of bispecific ADC logic gates including AND gate EGFR-cMET ADCs
  • Analyzing the maturing pipeline of multispecific ADCs to set the context of how antibody-led ADC innovation will translate to the clinic